Abstract
The COVID-19 pandemic has disrupted antimicrobial stewardship (AMS) activities in Hospital Queen Elizabeth II (HQEII), which has led to a surge in antibiotics consumption, particularly meropenem, vancomycin, piperacillin-tazobactam, ceftazidime, and ceftriaxone. This study aimed to compare the prevalence of antibiotics consumption in HQEII before (2018/2019) and during (2020/2021) the pandemic to explore its impact on antibiotic costs and bacterial resistance.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
